NMN
Nicotinamide mononucleotide, beta-NMN
The NAD precursor that the FDA banned from supplements in 2022 and quietly reinstated in 2025, with human trials that reliably raise NAD and much less reliably do anything else.
Human trials
Excluded from the dietary supplement definition by the FDA in October 2022 under the drug preclusion clause, then declared lawful in dietary supplements again in September 2025 following industry litigation. Not an approved drug for any indication.
What it is
NMN is one step from NAD in the salvage pathway. NAD is required for hundreds of reactions including every step of oxidative metabolism and the activity of sirtuins and PARPs, and it declines with age. Supplying a precursor to push NAD back up is the entire premise of this category.
Unlike injectable NAD+, NMN is oral, cheap and has actually been tested in randomised human trials.
The regulatory whiplash is worth understanding
In October 2022 the FDA determined that NMN was excluded from the dietary supplement definition. The reasoning was the drug preclusion clause in DSHEA: NMN had been authorised for investigation as a new drug before it was lawfully marketed as a supplement, and an ingredient in that position cannot be a supplement.
That decision reversed the agency's own prior treatment of the ingredient and was contested immediately. In September 2025, following litigation from the Natural Products Association, the FDA declared NMN lawful in dietary supplements again.
None of that sequence was about safety or efficacy. It was a statutory argument about which regulatory category the molecule belongs in, and it is a good illustration of why regulatory status and evidence are separate axes on this site.
What the trials show
Consistently, that NMN raises blood NAD in a dose-dependent way. That much is settled across multiple randomised placebo-controlled studies.
What is far less settled is whether the NAD rise produces anything worth having. Trials have reported modest effects on measures such as walking distance, aerobic capacity and insulin sensitivity in specific populations, with effect sizes that are small and results that have not consistently replicated. No trial has tested a clinical outcome that matters over a timeframe relevant to ageing, because that trial would take decades.
Raising a biomarker is the easy part.
Practical notes
- Product quality is the biggest practical problem. Independent testing has repeatedly found NMN products underdosed or containing negligible NMN. This is a market with poor quality control and a high price point.
- NMN and nicotinamide riboside are competing routes to the same place. Both raise NAD. There is no persuasive human evidence that either is superior, despite vigorous commercial claims in both directions.
- The oral precursors have the trials that the injections do not. If the goal is raising NAD, the evidence sits with the capsules, not the vials.
Side effects and warning signs
Commonly reported
- Generally well tolerated in trials, with adverse events close to placebo
- Nausea and bloating at higher doses
- Flushing, less common than with high-dose niacin
Stop and get medical help
- Any active malignancy. NAD is required for proliferation, and whether raising it systemically is wise in the presence of a tumour is genuinely unresolved
- Product identity is the practical risk. Independent testing has repeatedly found NMN products containing far less than labelled
Sources
From the community
Discussion for this compound concentrates in r/longevity and r/Biohackers.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.